Motility News

Certain dyspepsia symptoms, including early satiation and vomiting, were associated with an increased risk for poor response to proton pump inhibitors in patients with GERD, according to the results of an Italian study.

Two weeks of rifaximin therapy safely improved symptoms in patients — especially women — with functional dyspepsia in a Chinese randomized controlled trial.

Trulance safely and significantly improved constipation and related symptoms in adults with chronic idiopathic constipation, according to the results of a phase 3 randomized controlled trial.

A retrospective population-based study revealed associations between laparoscopic antireflux surgery and fewer postoperative complications, shorter hospital stays and lower health care costs vs. open procedures.

The FDA has approved a 72-µg dose of Linzess for adults with chronic idiopathic constipation, which Ironwood and Allergan expect to be available in the first quarter of 2017, the companies announced.

Trulance received FDA approval for the treatment of chronic idiopathic constipation, according to press releases from the manufacturer and the FDA.

After a positive recommendation from the European Medicines Agency, the European Commission has granted orphan drug designation to BB-301, an investigational therapy for the treatment of ocularpharyngeal muscular dystrophy, the manufacturer announced.

A group of European gastroenterologists has established a definition of failure of a treatment to provide adequate relief for patients with chronic constipation, focusing on five key symptoms and their severities.

Shionogi and Purdue Pharma have partnered to launch and commercialize naldemedine as Symproic in the U.S., according to a press release.

NEW ORLEANS — Proton pump inhibitors, used to treat heartburn and reduce stomach acid, may elevate risk for ischemic stroke, according to a presentation at the American Heart Association Scientific Sessions.